Effectiveness and Safety of Treatments for Coexisting Fibromyalgia and IBS
Overview
This systematic review evaluated oral treatments including pregabalin, cyclobenzaprine, probiotics, and MSG-restricted diets in adults with coexisting fibromyalgia syndrome (FMS) and irritable bowel syndrome (IBS). The review focused on pain reduction, psychological symptoms, quality of life, and safety, identifying variable efficacy across interventions and highlighting the need for personalized treatment approaches.
Background
Fibromyalgia syndrome (FMS) and irritable bowel syndrome (IBS) are chronic functional disorders frequently coexisting and significantly impairing quality of life. Both conditions share pathophysiological mechanisms such as central sensitization, neuroinflammation, and gut-brain axis disturbances, often accompanied by psychological comorbidities like anxiety and depression. Treatment is challenging due to multifactorial etiology and symptom overlap, necessitating multidimensional therapeutic strategies targeting both peripheral and central pathways. Current interventions include pharmacological agents, dietary modifications, and probiotics, but evidence on their efficacy and safety in comorbid patients remains limited.
Data Highlights
The systematic review included five randomized, double-blinded, placebo-controlled trials with adult patients diagnosed with both FMS and IBS. Interventions assessed were pregabalin (300–600 mg/day), cyclobenzaprine (10–30 mg/day), probiotics, and MSG-restricted diets. Primary outcomes focused on pain intensity measured by Visual Analog Scale (VAS), while secondary outcomes included depression scales (HAM-D, PHQ-9), global well-being (SF-36, FIQR), and health-related quality of life (HRQoL). Risk of bias was assessed using Cochrane RoB 2.0, and meta-analyses employed random-effects models calculating standardized mean differences (SMDs) with 95% confidence intervals.
Key Findings
Pregabalin demonstrated significant pain reduction compared to placebo, with improvements in sleep quality and some psychological symptoms.
Cyclobenzaprine showed modest benefits in pain relief and muscle relaxation but with variable effects on global well-being and quality of life.
Probiotics yielded inconsistent results, with some studies reporting gastrointestinal symptom improvement but no consistent impact on pain or psychological outcomes.
MSG-restricted diets were associated with symptom reduction in a subset of patients, suggesting neuroexcitatory modulation may benefit certain individuals.
All interventions were generally well tolerated, with safety profiles consistent with known adverse effects; however, heterogeneity in study designs and outcomes limited definitive conclusions.
Clinical Implications
Clinicians should consider pregabalin and cyclobenzaprine as potential pharmacological options for managing pain and associated symptoms in patients with coexisting FMS and IBS, while recognizing variable individual responses. Dietary modifications, including MSG restriction, and probiotics may offer adjunctive benefits but require personalized assessment. A multidimensional treatment approach addressing both central sensitization and gut-brain axis dysfunction is recommended to optimize patient outcomes.
Conclusion
This systematic review highlights the variable efficacy and safety of oral treatments for patients with coexisting fibromyalgia and irritable bowel syndrome. Personalized, multidimensional therapeutic strategies are essential to address the complex symptomatology and improve quality of life in this population.
References
Systematic Review 2024 -- Effectiveness and Safety of Treatments for Coexisting Fibromyalgia Syndrome and Irritable Bowel Syndrome
